A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are: * How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT? Participants will: * Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.
• Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Informed Consent Form;
• Participants with histologically or cytologically confirmed thymic carcinoma, and locally advanced or metastatic thymic carcinoma who are not suitable for curative intent therapy;
• Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy;
• Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor;
• At least one measurable target lesion that has not received radiotherapy according to RECIST v1.1;
• ECOG performance status score of 0 or 1;
• Expected survival ≥ 12 weeks;
• Adequate organ and bone marrow function.